Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | SLC9A3 | P48764 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | CNR1 | P21554 | 1/20 | 0.35 |
| ▸ | GLP1R | P43220 | 6/20 | 0.34 |
| ▸ | FAAH | O00519 | 3/20 | 0.34 |
| ▸ | LPAR1 | Q92633 | 2/20 | 0.34 |
| ▸ | LPAR2 | Q9HBW0 | 2/20 | 0.34 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.34 |
| ▸ | CASP2 | P42575 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24759042 | 0.90 | L3MBTL1 (0.41) | L3MBTL1SLC9A3TSHRCNR1GLP1R | |
| SCHEMBL21291226 | 0.88 | L3MBTL1 (0.44) | L3MBTL1SLC9A3TSHR | |
| SCHEMBL24759892 | 0.88 | TSHR (0.43) | L3MBTL1SLC9A3TSHRCNR1LPAR1 | |
| SCHEMBL21290595 | 0.88 | GAA (0.36) | L3MBTL1SLC9A3TSHRCNR1 | |
| SCHEMBL21291271 | 0.88 | TSHR (0.48) | L3MBTL1SLC9A3TSHRGLP1R | |
| SCHEMBL24840970 | 0.88 | L3MBTL1 (0.38) | L3MBTL1SLC9A3TSHR | |
| SCHEMBL25344641 | 0.87 | TSHR (0.47) | L3MBTL1SLC9A3TSHRGLP1R | |
| SCHEMBL31387542 | 0.86 | L3MBTL1 (0.57) | L3MBTL1TSHRCNR1FAAHLPAR1 | |
| SCHEMBL21290649 | 0.85 | L3MBTL1 (0.43) | L3MBTL1SLC9A3TSHRCNR1GLP1R | |
| SCHEMBL23178855 | 0.85 | TSHR (0.36) | L3MBTL1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024151991-A1 | RNAI AGENTS FOR INHIBITING INFLUENZA A VIRAL GENE EXPRESSION, COMPOSITIONS THEREOF, AND METHODS OF USE | Arrowhead Pharmaceuticals, Inc. (US) | 2024-07-18 | — | — | WO | disclosed |
| US-20220204976-A1 | RNAi Agents for Inhibiting Expression of HIF-2 alpha (EPAS1), Compositions Thereof, and Methods of Use | SIXTH STREETLENDING PARTNERS, AS THE ADMINISTRATIVE AGENT | 2022-06-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220204976-A1 | RNAi Agents for Inhibiting Expression of HIF-2 alpha (EPAS1), Compositions Thereof, and Methods of Use | EPAS1, HIF1AN, HIF1A | L3MBTL1 2349/4885SLC9A3 822/4885TSHR 2704/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.